Free Newsletter
WHO warns of bird flu vaccine shortage
While the threat of bird flu has largely vanished from the evening news, vaccine experts are acutely aware of the ever-present danger of a human outbreak.
One reason why bird flu fears have abated is that new bird flu vaccines have been approved and are being produced in quantity. But a new WHO-backed study indicates that the quantity that's available is still nowhere near the amount that would be needed to fight a global pandemic. It would take 18 months to manufacture sufficient quantities of bird flu vaccine to combat an outbreak, says the study. And meanwhile vaccine production capacity may be on the verge of being reduced.
"We still don't have enough production capability to cover the whole world in the early months of the pandemic... and what is worrying especially is that the capacity to make seasonal vaccines... is now much larger than the demand for these vaccines," says WHO vaccine expert Marie-Paule Kieny.
The key issue here, he adds, is that global demand for seasonal flu vaccine is 500 million doses a year. But production capacity has zoomed to 800 million doses and is on track to hit 1.7 million doses annually in only five years. As a result, WHO feels that producers may soon cut back on vaccine production, and once facilities are closed they will not be reopened easily.
- read the story from the AFP
Related Articles:
China stockpiles bird flu vax for possible outbreak
Officials warn of pandemic as public loses interest
Facing state barriers, flu jabs go unused
Seniors need high vaccine dose to prevent the flu
WHO warns of rising bird flu pandemic risk
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: